Abstract: In general, iPS cells are produced by delivery of stem cell-associated genes into adult somatic cells (e.g., fibroblasts). Described herein are methods for enhancing the efficiency and rate of induced pluripotent stem cell production by treating somatic cells with a transforming growth factor-beta receptor (TGF?R) inhibitor. Also described herein are iPS cell compositions made according to the methods described herein and iPS cell compositions comprising an iPS cell in an admixture with a TGF?R inhibitor. Further described herein are kits for producing iPS cells using a TGF?R inhibitor.

Abstract: In general, iPS cells are produced by delivery of stem cell-associated genes into adult somatic cells (e.g., fibroblasts). Described herein are methods for enhancing the efficiency and rate of induced pluripotent stem cell production by treating somatic cells with a transforming growth factor-beta receptor (TGF?R) inhibitor. Also described herein are iPS cell compositions made according to the methods described herein and iPS cell compositions comprising an iPS cell in an admixture with a TGF?R inhibitor. Further described herein are kits for producing iPS cells using a TGF?R inhibitor.

Abstract: This application relates to a method for selecting an induced pluripotent stem cell (iPS), the method comprising: selecting an iPS cell that expresses a gene in the Dlk1-Dio3 cluster from a population of iPS cells. The method further comprises: comparing the gene expression profile determined for an iPS cell with the gene expression profile determined for an embryonic stem cell; identifying a gene that is differentially expressed in the embryonic stem cell as compared to the iPS cell; and selecting the desired iPS cell from a population of iPS cells.

Abstract: In general, iPS cells are produced by delivery of stem cell-associated genes into adult somatic cells (e.g., fibroblasts). Described herein are methods for enhancing the efficiency and rate of induced pluripotent stem cell production by treating somatic cells with a transforming growth factor-beta receptor (TGF?R) inhibitor. Also described herein are iPS cell compositions made according to the methods described herein and iPS cell compositions comprising an iPS cell in an admixture with a TGF?R inhibitor. Further described herein are kits for producing iPS cells using a TGF?R inhibitor.

Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.

Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.

Abstract: Disclosed herein are methods to select for the generation of mouse and human pluripotent stem cells during developmental reprogramming. The methods described herein relate to the selection of induced pluripotent stem cells, i.e., pluripotent stem cells generated or induced from differentiated cells without a requirement for genetic selection. Described herein are particular embodiments for selection of reprogrammed cells based on 1) colony morphology, or 2) X chromosome reactivation in female cells.

Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.

Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.

Abstract: Described herein is a method for reprogramming a somatic cell using an inducible lentiviral vector that permits the expression of stem-cell associated genes to be turned off or on as necessary by one of skill in the art. Inducible expression of stem-cell associated genes permits the genes to be expressed until such time that induction of iPS cells occurs and then expression can be turned off to prevent the pathological growth of cells leading to e.g., cancer or teratoma. Also described herein are secondary cell compositions, the use of which can speed the production of iPS cells, providing for a faster, more efficient system for iPS cell induction.

Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.

Abstract: A method of correcting of treating a genetic disorder by combining therapeutic cloning and gene therapy.